Limits...
Wandering Ozurdex(®) implant.

Bansal R, Bansal P, Kulkarni P, Gupta V, Sharma A, Gupta A - J Ophthalmic Inflamm Infect (2011)

Bottom Line: Retrospective chart review of three eyes with PLV aphakia (three patients with uveitis) who received intravitreal injection of Ozurdex(®) for cystoid macular edema (one eye), persistent inflammation (one eye), and ocular hypotony (one eye).Two eyes developed corneal edema, of which one eye underwent implant removal from the AC.Ozurdex(®) implant should be contraindicated in eyes with PLV aphakia to avoid its deleterious effect on the corneal endothelium.

View Article: PubMed Central - PubMed

Affiliation: Advanced Eye Center, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

ABSTRACT

Purpose: To report the behavior of intravitreal Ozurdex(®) implant in eyes with post-lensectomy-vitrectomy (PLV) aphakia.

Methods: Retrospective chart review of three eyes with PLV aphakia (three patients with uveitis) who received intravitreal injection of Ozurdex(®) for cystoid macular edema (one eye), persistent inflammation (one eye), and ocular hypotony (one eye). Final outcome was assessed in terms of effectiveness, stability, and tolerance of the implant.

Results: Following the implant, an initial improvement was seen in all the three eyes. However, the implant migrated into the anterior chamber (AC) at 1 week in two eyes and at 5 weeks in one eye, and wandered between the AC and vitreous cavity with changing postures of the patient. Two eyes developed corneal edema, of which one eye underwent implant removal from the AC.

Conclusion: Ozurdex(®) implant should be contraindicated in eyes with PLV aphakia to avoid its deleterious effect on the corneal endothelium.

No MeSH data available.


Related in: MedlinePlus

Slit lamp photograph of anterior segment of the right eye, following pars plana lensectomy and vitrectomy with SF6 tamponade with intravitreal injection of Ozurdex® for complicated cataract, in a 15-year-old male (case 3) showing migration of implant into the AC, 5 weeks after the surgery
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3302995&req=5

Fig3: Slit lamp photograph of anterior segment of the right eye, following pars plana lensectomy and vitrectomy with SF6 tamponade with intravitreal injection of Ozurdex® for complicated cataract, in a 15-year-old male (case 3) showing migration of implant into the AC, 5 weeks after the surgery

Mentions: A 15-year-old male with idiopathic chronic anterior uveitis in the right eye since 4 years had BCVA 6/36 and IOP 6 mmHg. The left eye was normal. He had significant cataract in the right eye and underwent PPL and PPV. Intraoperatively, atrophy of ciliary processes was noted along with multiple peripheral retinal breaks. An internal tamponade with SF6 was done along with intravitreal injection of Ozurdex®. At 3 weeks postoperative, the BCVA was 6/12 and IOP was 18 mmHg. The eye was quiet, and the Ozurdex® implant was well placed in the vitreous cavity inferiorly. At 5 weeks, the implant was found lying inferiorly in the AC (Fig. 3). The BCVA was 6/12, and IOP was 8 mmHg. The cornea was clear. The implant migrated back into the vitreous cavity once the patient attained supine position. On his last visit at 4 months, the BCVA was 6/6, IOP 12 mmHg, and the eye was quiescent with the implant in the vitreous cavity.Fig. 3


Wandering Ozurdex(®) implant.

Bansal R, Bansal P, Kulkarni P, Gupta V, Sharma A, Gupta A - J Ophthalmic Inflamm Infect (2011)

Slit lamp photograph of anterior segment of the right eye, following pars plana lensectomy and vitrectomy with SF6 tamponade with intravitreal injection of Ozurdex® for complicated cataract, in a 15-year-old male (case 3) showing migration of implant into the AC, 5 weeks after the surgery
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3302995&req=5

Fig3: Slit lamp photograph of anterior segment of the right eye, following pars plana lensectomy and vitrectomy with SF6 tamponade with intravitreal injection of Ozurdex® for complicated cataract, in a 15-year-old male (case 3) showing migration of implant into the AC, 5 weeks after the surgery
Mentions: A 15-year-old male with idiopathic chronic anterior uveitis in the right eye since 4 years had BCVA 6/36 and IOP 6 mmHg. The left eye was normal. He had significant cataract in the right eye and underwent PPL and PPV. Intraoperatively, atrophy of ciliary processes was noted along with multiple peripheral retinal breaks. An internal tamponade with SF6 was done along with intravitreal injection of Ozurdex®. At 3 weeks postoperative, the BCVA was 6/12 and IOP was 18 mmHg. The eye was quiet, and the Ozurdex® implant was well placed in the vitreous cavity inferiorly. At 5 weeks, the implant was found lying inferiorly in the AC (Fig. 3). The BCVA was 6/12, and IOP was 8 mmHg. The cornea was clear. The implant migrated back into the vitreous cavity once the patient attained supine position. On his last visit at 4 months, the BCVA was 6/6, IOP 12 mmHg, and the eye was quiescent with the implant in the vitreous cavity.Fig. 3

Bottom Line: Retrospective chart review of three eyes with PLV aphakia (three patients with uveitis) who received intravitreal injection of Ozurdex(®) for cystoid macular edema (one eye), persistent inflammation (one eye), and ocular hypotony (one eye).Two eyes developed corneal edema, of which one eye underwent implant removal from the AC.Ozurdex(®) implant should be contraindicated in eyes with PLV aphakia to avoid its deleterious effect on the corneal endothelium.

View Article: PubMed Central - PubMed

Affiliation: Advanced Eye Center, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

ABSTRACT

Purpose: To report the behavior of intravitreal Ozurdex(®) implant in eyes with post-lensectomy-vitrectomy (PLV) aphakia.

Methods: Retrospective chart review of three eyes with PLV aphakia (three patients with uveitis) who received intravitreal injection of Ozurdex(®) for cystoid macular edema (one eye), persistent inflammation (one eye), and ocular hypotony (one eye). Final outcome was assessed in terms of effectiveness, stability, and tolerance of the implant.

Results: Following the implant, an initial improvement was seen in all the three eyes. However, the implant migrated into the anterior chamber (AC) at 1 week in two eyes and at 5 weeks in one eye, and wandered between the AC and vitreous cavity with changing postures of the patient. Two eyes developed corneal edema, of which one eye underwent implant removal from the AC.

Conclusion: Ozurdex(®) implant should be contraindicated in eyes with PLV aphakia to avoid its deleterious effect on the corneal endothelium.

No MeSH data available.


Related in: MedlinePlus